Compare HMC & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMC | NTRA |
|---|---|---|
| Founded | 1946 | 2003 |
| Country | Japan | United States |
| Employees | 215320 | N/A |
| Industry | Auto Manufacturing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0B | 29.1B |
| IPO Year | N/A | 2015 |
| Metric | HMC | NTRA |
|---|---|---|
| Price | $26.44 | $212.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | N/A | ★ $259.07 |
| AVG Volume (30 Days) | ★ 2.1M | 1.3M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.45% | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,939,000.00 |
| Revenue This Year | N/A | $18.08 |
| Revenue Next Year | $4.36 | $19.65 |
| P/E Ratio | $40.40 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.25 | $131.81 |
| 52 Week High | $34.89 | $256.36 |
| Indicator | HMC | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 51.89 | 51.37 |
| Support Level | $26.09 | $186.96 |
| Resistance Level | $26.66 | $222.53 |
| Average True Range (ATR) | 0.44 | 10.51 |
| MACD | -0.08 | 0.34 |
| Stochastic Oscillator | 17.55 | 51.46 |
Incorporated in 1948, Honda Motor was originally a motorcycle manufacturer. Today, the firm makes automobiles, motorcycles, and power products such as boat engines, generators, and lawnmowers. Including joint ventures, Honda sold 3.4 million light vehicles and 22.1 million motorcycles in fiscal 2026, and consolidated sales were JPY 21.8 trillion. Automobiles constitute 64% of revenue and motorcycles 18%, with the rest split between power products and financial services. Honda also makes robots and private jets.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.